CONTEMPORARY TOPICS IN
THYROID CANCER

FRIDAY, SEPTEMBER 12, 2014

A continuing education service of Penn State College of Medicine and Penn State Hershey Cancer Institute

Hershey Lodge and Convention Center
325 University Drive
Hershey, PA 17033
PURPOSE AND OVERVIEW

Since the early 1970s, the incidence of thyroid cancer has more than doubled, and the current national disease prevalence is estimated at 300,000 affected people.

Approximately, 62,980 new cases of thyroid carcinoma were diagnosed in the United States during 2014, with 1,890 deaths from the disease.

Clinicians and researchers have recently gained an increased understanding of the biology of thyroid cancers. Concurrently, the availability of multiple novel molecular agents with the potential to impact the disease has resulted in the launch of several ongoing clinical studies evaluating the role of medical management for locally advanced or disseminated thyroid cancer. Exciting early efficacy and safety findings have been presented to the oncology community, offering new hope of beneficial treatments for patients with no prior therapeutic opportunity. In order to offer optimal patient care—including the option of clinical trial participation—the practicing medical oncologist must be well informed of these advances. By providing access to the latest research developments and expert perspectives on the disease, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

AUDIENCE

Otolaryngologists, endocrine surgeons, endocrinologists, medical oncologists, radiation oncologists, primary care physicians, general surgeons, surgical oncologists, hematology/oncology fellows, oncology nurses, medical and surgical residents, physician assistants and nurse practitioners.
OBJECTIVES

Describe the increasing incidence, long-term natural history and molecular characteristics of thyroid cancer.

Develop a treatment algorithm for advanced, asymptomatic and symptomatic thyroid cancer.

Recognize the acute and chronic side effects of radioactive iodine treatment, and identify the clinical and laboratory signs of iodine-refractory thyroid cancer.

Appraise the emerging safety and efficacy data on multikinase inhibitor therapy for patients with advanced thyroid cancer.

Discuss the pathophysiology and epidemiology of differentiated, medullary and anaplastic thyroid cancer.

Develop a clinical algorithm for the management of early and advanced thyroid cancer, including the roles of surgery, 131I and thyroxine therapy, radiation therapy and chemotherapy.

Understand the biologic rationale for the limited effectiveness of chemotherapy in patients with advanced thyroid cancer.

CREDIT

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Penn State College of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Complete faculty disclosure will be provided to program participants at the beginning of the activity.
FACULTY

SALAH ALMOKADEM, MD*
Assistant Professor of Medicine
Division of Hematology/Oncology

MARIA J. BAKER, PHD, FACMG, MS, LGC*
Associate Professor of Medicine
Division of Hematology/Oncology

HENRY CRIST, MD*
Associate Professor
Division of Anatomic Pathology

ROBERT L. FERRIS, MD, PHD, FACS
Keynote Speaker
UPMC Endowed Professor and Chief
Division of Head and Neck Surgery
Associate Director for Translational Research
Co-Leader, Cancer Immunology Program
University of Pittsburgh Cancer Institute

DAVID GOLDENBERG, MD, FACS*
Co-Chair, Professor of Surgery and Medicine
Chief, Division of Otolaryngology
Head and Neck Surgery

RAYMOND J. HOHL, MD, PHD*
Professor of Medicine and Pharmacology
Director, Penn State Hershey Cancer Institute
University Professorship in Medicine, Oncology

CHRISTOPHER HOLLENBEAK, PHD*
Professor of Surgery and Public Health Sciences
Chief, Division of Outcomes Research and Quality

RICKHESVAR P.M. MAHRAJ, MD, FRCP, FRCR*
Professor of Radiology and Pediatrics
Vice Chair for Strategic Development
Division Chief, Thoracic Radiology
Director of Procedure Suite

ANDREA MANNI, MD*
Professor of Medicine
Chief, Division of Endocrinology
Division of Endocrinology, Diabetes and Metabolism

BRIAN SAUNDERS, MD, FACS*
Co-Chair, Associate Professor of Surgery and Medicine
Division of General Surgery Specialties and Surgical Oncology

* Penn State Milton S. Hershey Medical Center; Penn State Hershey Cancer Institute; Penn State College of Medicine, Hershey, PA
PROGRAM

11:30AM REGISTRATION AND BUFFET LUNCHEON

11:55 WELCOME
David Goldenberg, MD, FACS

12:00 INTRODUCTION
Raymond J. Hohl, MD, PhD

12:10 EPIDEMIOLOGY AND FINANCIAL IMPACT OF THYROID CANCER
Christopher Hollenbeak, PhD

12:25 ULTRASOUND IN THYROID CANCER
Rickhesvar P.M. Mahraj, MD, FRCP, FRCR

~ Q&A

12:40 PATHOLOGY IN THYROID CANCER
Henry Crist, MD

12:55 SURGICAL MANAGEMENT OF THYROID CANCER
Brian Saunders, MD, FACS

1:10 MANAGEMENT OF THE NECK IN THYROID CANCER
David Goldenberg, MD, FACS

~ Q&A

1:25 Keynote: GENE EXPRESSION TESTS IN THE DIAGNOSIS OF THYROID CANCER
Robert L. Ferris, MD, PhD, FACS

2:00 BREAK

2:15 ENDOCRINE AND RADIOIODINE MANAGEMENT OF THYROID CANCER
Andrea Manni, MD

2:35 ONCOLOGICAL MANAGEMENT OF ADVANCED THYROID CANCER
Salah Almokadem, MD

2:55 UPDATE ON HEREDITARY THYROID CANCER
Maria J. Baker, PhD, FACMG, MS, LGC

~ Q&A

3:15 CASE PRESENTATIONS AND DISCUSSIONS
Moderator: David Goldenberg, MD, FACS

4:10 PROGRAM EVALUATION AND ADJOURNMENT
FEE
$25 per person
Includes:
Cost of Instruction • Refreshments • Handout Materials • Buffet Lunch

CANCELLATION POLICY
The University reserves the right to cancel or postpone any course or activity because of insufficient enrollment or other unforeseen circumstances.

NO REFUNDS
After September 8, 2014
Substitutes are accepted at any time

Please provide a cell phone number so we can reach you in the event of last-minute changes or cancellation. If a program is canceled or postponed, the University will refund registration fees but cannot be held responsible for any related costs, charges, or expenses, including cancellation/change charges assessed by airlines or travel agencies. Preregistered participants will be notified if a program is filled or canceled.

REGISTRATION

DEADLINE
September 8, 2014

Registrations will be confirmed by email. If you do not receive confirmation from Penn State within two weeks, phone Continuing Education at 717-531-6483 to confirm your registration. Walk-ins and late registrations can be accepted only if space is available.

TO REGISTER
Call 717-531-6483
Fax 717-531-5604
Email ContinuingEd@hmc.psu.edu
Mail Registrar, Penn State Hershey
Continuing Education, G220
P. O. Box 851, Hershey, PA 17033

Register Online Today!
pennstatehershey.org.ce
CONTEMPORARY TOPICS IN
THYROID CANCER
FRIDAY, SEPTEMBER 12, 2014

Register Online Today!
pennstatehershey.org.ce